Evidence map›Paper›PMID 12360404›Full record

ArticleOncogene2002

Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function.

Thérèse David-Pfeuty, Yolande Nouvian-Dooghe

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. p14Nature communications · 2024
    Article
  3. p14Research square · 2023
    Article
  4. Article
  5. Review
  6. DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.Journal of molecular histology · 2006
    Review
  7. Article
  8. Article
  9. The moving parts of the nucleolus.Histochemistry and cell biology · 2005
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Thérèse David-PfeutyUMR 146 du CNRS, Institut Curie-Recherche, Bâtiment 110, Centre Universitaire, 91405 Orsay Cédex, France. Thérèse.Pfeuty@curie.u-psud.fr
Yolande Nouvian-Dooghe
Institut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.

Indexed as

CDC2-CDC28 KinasesCell CycleCell NucleolusCyclin-Dependent Kinase 2Cyclin-Dependent KinasesCyclin ECytoplasmDual-Specificity PhosphatasesHeLa CellsHumansKi-67 AntigenMitosisProtein Serine-Threonine KinasesProtein Tyrosine PhosphatasesPurinesRoscovitineCDC2-CDC28 KinasesCDK2 protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent KinasesCyclin EDual-Specificity PhosphatasesDUSP5 protein, humanKi-67 AntigenProtein Serine-Threonine KinasesProtein Tyrosine PhosphatasesPurinesRoscovitineTumor Suppressor Protein p14ARFTumor Suppressor Protein p53

Identifiers

PMID12360404
OpenAlexW2047734709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.